Tissue Regenix Group plc
TRX.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | £0 | £0 | £0 | £0 |
| - Cash | £0 | £0 | £0 | £0 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | £0 | £0 | £0 | £0 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | -2.9% | 20.5% | 24% | – |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | 47.5% | 47.6% | 37.3% | 28.5% |
| EBITDA | £0 | £0 | -£0 | -£0 |
| % Margin | 4.8% | 1.5% | -4.2% | -15.4% |
| Net Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -2.5% | -5.8% | -11% | -24.3% |
| EPS Diluted | -0.01 | -0.024 | -0.031 | -0.068 |
| % Growth | 58.4% | 21.9% | 54.3% | – |
| Operating Cash Flow | -£0 | £0 | -£0 | -£0 |
| Capital Expenditures | -£0 | -£0 | -£0 | -£0 |
| Free Cash Flow | -£0 | £0 | -£0 | -£0 |